TheraIndx Lifesciences cancer biology platform is transforming drug repurposing by seamlessly integrating advanced computational intelligence with well-established preclinical validation capabilities. By systematically mining multi-omics data, disease-specific signaling networks, and real-world biological evidence, they identify high-confidence repurposing opportunities for existing drugs—both as standalone therapies and in novel combinations. What truly differentiates their approach is the tight coupling of in-silico discovery with rigorous wet-lab validation across relevant cell-based, organoid, and in-vivo models. This end-to-end framework enables rapid biological confirmation, robust biomarker identification, and patient stratification, significantly de-risking development while accelerating the translation of repurposed assets into clinically meaningful oncology programs.